5α-Reductase Inhibitor Use in Patients With Prostate Cancer-Reply

Affiliations

Comment

Reith R Sarkar et al. JAMA Intern Med. 2019.

. 2019 Oct 1;179(10):1440-1441.

doi: 10.1001/jamainternmed.2019.3620.

¹ Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla.

No abstract available

Comment on

Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR, Parsons JK, Bryant AK, Ryan ST, Kader AK, McKay RR, D'Amico AV, Nguyen PL, Hulley BJ, Einck JP, Mundt AJ, Kane CJ, Murphy JD, Rose BS. Sarkar RR, et al. JAMA Intern Med. 2019 Jun 1;179(6):812-819. doi: 10.1001/jamainternmed.2019.0280. JAMA Intern Med. 2019. PMID: 31058923 Free PMC article.
5α-Reductase Inhibitor Use in Patients With Prostate Cancer.
Medina CA, Zuluaga L, Plata M. Medina CA, et al. JAMA Intern Med. 2019 Oct 1;179(10):1439. doi: 10.1001/jamainternmed.2019.3623. JAMA Intern Med. 2019. PMID: 31589257 No abstract available.
5α-Reductase Inhibitor Use in Patients With Prostate Cancer.
Thompson IM Jr, Tangen CM, Kramer B. Thompson IM Jr, et al. JAMA Intern Med. 2019 Oct 1;179(10):1440. doi: 10.1001/jamainternmed.2019.3626. JAMA Intern Med. 2019. PMID: 31589258 No abstract available.